IN2014DN03063A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03063A
IN2014DN03063A IN3063DEN2014A IN2014DN03063A IN 2014DN03063 A IN2014DN03063 A IN 2014DN03063A IN 3063DEN2014 A IN3063DEN2014 A IN 3063DEN2014A IN 2014DN03063 A IN2014DN03063 A IN 2014DN03063A
Authority
IN
India
Prior art keywords
heterocyclyl
heteroaryl
substituted
cyclic group
phenyl
Prior art date
Application number
Inventor
Karl Richard Gibson
Dafydd Rhys Owen
Original Assignee
Inhibitaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitaxin Ltd filed Critical Inhibitaxin Ltd
Publication of IN2014DN03063A publication Critical patent/IN2014DN03063A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The invention provides compounds of formula I (I) wherein: R represents a cyclic group selected from phenyl heteroaryl heterocyclyl and C 3 6 cycloalkyl;10 wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo C 6 alkyloptionally substituted with 1 3 halogen atoms phenyl C 6 alkoxy optionally substituted with 1 3 halogen atoms cyano heteroaryl 1a andheterocyclyl 1a; and wherein each cyclic group is optionally fused to a benzene ring or a 5 or 1 6 membered heteroaromaticor heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl and heterocyclyl 1a may additionally be substituted with =O;20 X represents a bond or C 6 alkylene (which may be straight or branched); R 2 represents H or C 6 alkyl; R 3 represents H or C 6 alkyl; Y represents a bond or C 6 alkylene (which may be straight or branched and optionally substituted with OH or CF 3 );2 R 4 represents a cyclic group selected from phenyl heteroaryl 4 heterocyclyl 4 and C 3 6 cycloalkyl; wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo C 6 alkyloptionally substituted with 1 3 halogen atoms TET01063WO 4 phenyl C 6 alkylsubstituted with phenyl C 6 alkoxy optionally substituted with 3 halogen atoms cyano heteroaryl 4a andheterocyclyl 4a; and wherein each cyclic group is optionally fused to benzene ring or a 5 or 6 membered heteroaromaticor heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl 4 and heterocyclyl 4a may additionally be substituted with =O; heteroaryl heteroaryl 1a heteroaryl 4 and heteroaryl 4a independently represent a 5 or 6 membered heteroaryl group containing from 1 to 3 heteroatoms (selected from N O and 10 S); and heterocyclyl heterocyclyl 1a heterocyclyl 4 and heterocyclyl 4a independently represent a 5 or 6 membered heterocyclyl group containing from 1 to 3 heteroatoms (selected from N O and S); and pharmaceutically acceptable salts and solvates thereof.1 The compounds are useful as pharmaceuticals particularly in the treatment of fibrotic diseases cancer and pain.
IN3063DEN2014 2011-10-28 2012-10-26 IN2014DN03063A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552651P 2011-10-28 2011-10-28
PCT/IB2012/055918 WO2013061297A1 (en) 2011-10-28 2012-10-26 Pyridazine Derivatives Useful in Therapy

Publications (1)

Publication Number Publication Date
IN2014DN03063A true IN2014DN03063A (en) 2015-05-15

Family

ID=47326250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3063DEN2014 IN2014DN03063A (en) 2011-10-28 2012-10-26

Country Status (9)

Country Link
US (2) US9273011B2 (en)
EP (2) EP3243815B1 (en)
JP (1) JP6158817B2 (en)
CN (2) CN103958481B (en)
CA (1) CA2853231C (en)
ES (2) ES2648901T3 (en)
HK (2) HK1200455A1 (en)
IN (1) IN2014DN03063A (en)
WO (1) WO2013061297A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499591B (en) * 2013-01-11 2015-09-11 Lilly Co Eli Bicyclic pyrimidine compounds
AR095328A1 (en) 2013-03-15 2015-10-07 Biogen Idec Inc S1P AND / OR ATX MODULATION AGENTS
AU2014352888B2 (en) 2013-11-22 2019-05-09 Sabre Therapeutics Llc Autotaxin inhibitor compounds
WO2015154023A1 (en) 2014-04-04 2015-10-08 X-Rx Discovery, Inc. Substituted spirocydic inhibitors of autotaxin
CN107205972A (en) * 2014-04-23 2017-09-26 X-Rx股份有限公司 Substituted N (2 (amino) 2 oxoethyl) the benzamide inhibitor of autocrine motility factor and their preparation and the purposes in disease that treatment LPA is relied on or that LPA is mediated
TW201623239A (en) 2014-04-24 2016-07-01 田邊三菱製藥股份有限公司 Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medical use thereof
AR100767A1 (en) 2014-06-06 2016-11-02 Biogen Ma Inc ATX MODULATING AGENTS
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CN116059203A (en) 2015-05-27 2023-05-05 赛博治疗有限责任公司 Autotaxin inhibitors and uses thereof
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
AU2019311595B2 (en) 2018-07-27 2024-01-04 Mitsubishi Tanabe Pharma Corporation Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
DK3873472T3 (en) 2018-10-29 2023-09-04 Boehringer Ingelheim Int NEW PYRIDAZINES
US11465982B2 (en) * 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
BR112021026267A2 (en) * 2019-07-22 2022-05-31 Boehringer Ingelheim Int n-Methyl, n-((6-(methoxy)pyridazin-3-yl)amine derivatives as autotaxin (atx) modulators for the treatment of fibrotic or inflammatory airway diseases
US11485727B2 (en) * 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
AU2020342202B2 (en) * 2019-09-06 2023-07-06 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Pyrimidine compound and preparation method therefor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7459285B2 (en) 2002-12-10 2008-12-02 Echelon Biosciences Incorporated Compounds and methods of use thereof for assaying lysophospholipase D activity
AR051094A1 (en) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
GB0517184D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AU2007243280A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
PT2076508E (en) 2006-10-18 2011-03-07 Pfizer Prod Inc Biaryl ether urea compounds
JP5361857B2 (en) 2007-03-23 2013-12-04 ファイザー・リミテッド Ion channel inhibitors
WO2008123469A1 (en) * 2007-03-30 2008-10-16 Japan Tobacco Inc. Six-membered amide compound and use thereof
EA015952B1 (en) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-pyridinecarboxamide derivatives as sodium channel modulators
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
DE102007047738A1 (en) * 2007-10-05 2009-04-09 Merck Patent Gmbh imidazole derivatives
DE102007047737A1 (en) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidine and piperazine derivatives
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
CA2764818A1 (en) * 2009-06-08 2010-12-16 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
AR081626A1 (en) * 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
JP2012072067A (en) * 2010-09-28 2012-04-12 Astellas Pharma Inc Nitrogen containing aromatic heterocyclic compound

Also Published As

Publication number Publication date
EP2771325B1 (en) 2017-06-28
HK1200455A1 (en) 2015-08-07
EP2771325A1 (en) 2014-09-03
HK1246783A1 (en) 2018-09-14
EP3243815B1 (en) 2019-07-10
CN106220572A (en) 2016-12-14
JP2014530902A (en) 2014-11-20
US10016420B2 (en) 2018-07-10
US20140275100A1 (en) 2014-09-18
CN106220572B (en) 2019-12-13
ES2648901T3 (en) 2018-01-08
JP6158817B2 (en) 2017-07-05
CA2853231A1 (en) 2013-05-02
WO2013061297A1 (en) 2013-05-02
CA2853231C (en) 2020-08-04
ES2748656T3 (en) 2020-03-17
CN103958481B (en) 2017-06-30
EP3243815A1 (en) 2017-11-15
US20160287584A1 (en) 2016-10-06
US9273011B2 (en) 2016-03-01
CN103958481A (en) 2014-07-30

Similar Documents

Publication Publication Date Title
IN2014DN03063A (en)
CY1118572T1 (en) CYCLOGAL PRODUCTION
IN2014MN02106A (en)
NZ703064A (en) Inhibitors of hepatitis c virus
EA201690019A1 (en) AMINOTRIASIN DERIVATIVE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION
NZ708801A (en) Aryl and heteroaryl fused lactams
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX362550B (en) Heterocyclic inhibitors of glutaminase.
MD20140037A2 (en) (4-Phenylimidazol-2-yl)ethylamine derivatives useful as sodium channel modulators
IN2014MN02658A (en)
IN2014MN02459A (en)
AU2018253590A1 (en) Imidazopyridazine compounds
MD20150075A2 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MY194711A (en) Novel annelated phenoxyacetamides
NZ712660A (en) Dicarboxylic acid compound
EA201591649A1 (en) COMPOSITIONS WITH ORGANIC COMPOUNDS
EA201590074A1 (en) BENZODIOXOL DERIVATIVE, METHOD FOR ITS PREPARATION AND ITS APPLICATION
MX2018010177A (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds.
EA201690924A1 (en) Fluorphenylpyrazole compounds
EA201491982A1 (en) ANTIBACTERIAL QUINOLINE DERIVATIVES
NZ764463A (en) Heterocyclic compound and application thereof in medicine
MX2015002705A (en) Pyridinone compounds for use in photodynamic therapy.
EA201200267A1 (en) NEW COMPOUNDS OF DIHYDROXAZOLOBENZODIAZEPINONA, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS THEM CONTAINING
PH12015502060A1 (en) Hydrochloride salts of an antibiotic compound
AU2012296262A8 (en) Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors